In detail, cblb-deficient animals are able to reject implanted TC-1 lung fibroblast tumors [17], [18], EL-4 lymphomas [19], E.G7 lymphomas [20], B16ova melanomas [21], disseminated leukemia [22], mammary adenocarcinomas [23] as well as spontaneous UVB induced skin tumors [17], and genetically induced T cell lymphomas [20]. This evidence concerns the gene CBLB and lymphoma.